Highly potent (IC50 uMEK1 = 0.7 nM, pp-MEK1 = 14.9 nM)1 and selective MEK inhibitor displaying selective inhibition of proliferation in various BRAF mutant cancer cell lines (IC50 ACHN = 9.8 nM; IC50 HT-29 = 0.57 nM). Can limit outgrowth of tumors without directly inhibiting tumor cell proliferation via abrogation of cytokine-driven expansion of monocytic myeloid-derived suppressor cells (mMDSC) through a mechanism involving CD8+ T cells. Displays potent anti-arthritic effects. Approved for use against unresectable or metastatic BRAF-mutant melanoma alone or in combination with Dabrafenib.; Purity: > 98%; Molecular Weight: 615.39; Form/Appearance: powder, 50 mg